JP Morgan Chase
TRVI icon

JP Morgan Chase’s Trevi Therapeutics TRVI Stock Holding History

JP Morgan Chase’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
73,273
+2,642
+4% +$38.4K ﹤0.01% 4464
2026
Q1 		$790K Buy
70,631
+11,156
+19% +$125K ﹤0.01% 4741
2025
Q4 		$745K Buy
59,475
+660
+1% +$7.63K ﹤0.01% 4785
2025
Q3 		$538K Buy
58,815
+4,473
+8% +$33.5K ﹤0.01% 4981
2025
Q2 		$297K Sell
54,342
-9,110
-14% -$56.7K ﹤0.01% 5033
2025
Q1 		$399K Sell
63,452
-158,212
-71% -$755K ﹤0.01% 4909
2024
Q4 		$913K Buy
221,664
+121,147
+121% +$388K ﹤0.01% 4701
2024
Q3 		$336K Buy
100,517
+69,167
+221% +$206K ﹤0.01% 5143
2024
Q2 		$93.4K Buy
31,350
+5,887
+23% +$16.4K ﹤0.01% 5544
2024
Q1 		$87.8K Sell
25,463
-1,520
-6% -$3.39K ﹤0.01% 5726
2023
Q4 		$36.2K Sell
26,983
-2
-0% -$3 ﹤0.01% 6104
2023
Q3 		$58.8K Sell
26,985
-6,189
-19% -$14K ﹤0.01% 5738
2023
Q2 		$79.3K Buy
+33,174
New +$83.6K ﹤0.01% 5563
2020
Q4 		– Sell
-3
Closed – – 5933
2020
Q3 		$0 Hold
3
– – ﹤0.01% 5783
2020
Q2 		$0 Buy
+3
New +$11 ﹤0.01% 5703

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

JP Morgan Chase's TRVI Position: Q2 2026 in Review

JP Morgan Chase increased its Trevi Therapeutics (TRVI) stake by 3.7% in Q2 2026, buying an estimated $38.4K and bringing the position to 73,273 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #4464.

JP Morgan Chase first reported a position in TRVI in Q2 2020 and has held it in 15 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • JP Morgan Chase held 73,273 shares of Trevi Therapeutics worth $1.37M as of Q2 2026.
  • JP Morgan Chase bought 2,642 Trevi Therapeutics shares in Q2 2026, an estimated $38.4K.
  • Trevi Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4464 holding.
  • JP Morgan Chase first reported a position in Trevi Therapeutics in Q2 2020 and has held it in 15 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.